[go: up one dir, main page]

WO2010040096A3 - Procédés pour le traitement d’une réaction de greffe contre hôte - Google Patents

Procédés pour le traitement d’une réaction de greffe contre hôte Download PDF

Info

Publication number
WO2010040096A3
WO2010040096A3 PCT/US2009/059437 US2009059437W WO2010040096A3 WO 2010040096 A3 WO2010040096 A3 WO 2010040096A3 US 2009059437 W US2009059437 W US 2009059437W WO 2010040096 A3 WO2010040096 A3 WO 2010040096A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
host disease
treatment
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/059437
Other languages
English (en)
Other versions
WO2010040096A2 (fr
Inventor
Mohammad S. Hossain
Andrew T. Gewitz
John D. Roback
Edmund K. Waller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Priority to US13/121,016 priority Critical patent/US8486408B2/en
Priority to CA2739454A priority patent/CA2739454C/fr
Priority to EP09793293A priority patent/EP2349291B1/fr
Priority to AU2009298122A priority patent/AU2009298122B2/en
Publication of WO2010040096A2 publication Critical patent/WO2010040096A2/fr
Publication of WO2010040096A3 publication Critical patent/WO2010040096A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour traiter ou prévenir une réaction de greffe contre hôte chez un sujet. Les procédés comprennent la sélection d’un sujet nécessitant un traitement pour une réaction de greffe contre hôte; et l’administration au sujet d’une quantité thérapeutiquement efficace d’un agoniste de TLR5 tel que le polypeptide flagelline, ou un polynucléotide codant pour la flagelline, de manière à traiter ou prévenir une réaction de greffe contre hôte chez le sujet. La présente invention concerne en outre des procédés pour réduire la susceptibilité d’infection opportuniste chez un sujet qui est un receveur de greffe de moelle osseuse. Les procédés comprennent la sélection d’un sujet qui a subi une transplantation de moelle osseuse ou de cellules souches hématopoïétiques; et l’administration au sujet d’une quantité thérapeutiquement efficace d’un agoniste de TLR5 tel qu’un polypeptide de flagelline ou un polynucléotide codant pour le polypeptide, et l’administration au sujet d’une quantité efficace d’antigène de l’infection opportuniste, de manière à réduire la susceptibilité d’infection opportuniste chez le sujet.
PCT/US2009/059437 2008-10-03 2009-10-02 Procédés pour le traitement d’une réaction de greffe contre hôte Ceased WO2010040096A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/121,016 US8486408B2 (en) 2008-10-03 2009-10-02 Methods for the treatment of graft-versus-host disease
CA2739454A CA2739454C (fr) 2008-10-03 2009-10-02 Procedes pour le traitement d'une reaction de greffe contre hote
EP09793293A EP2349291B1 (fr) 2008-10-03 2009-10-02 Procédés pour le traitement d une réaction de greffe contre hôte
AU2009298122A AU2009298122B2 (en) 2008-10-03 2009-10-02 Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10264808P 2008-10-03 2008-10-03
US61/102,648 2008-10-03

Publications (2)

Publication Number Publication Date
WO2010040096A2 WO2010040096A2 (fr) 2010-04-08
WO2010040096A3 true WO2010040096A3 (fr) 2010-05-27

Family

ID=41818363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059437 Ceased WO2010040096A2 (fr) 2008-10-03 2009-10-02 Procédés pour le traitement d’une réaction de greffe contre hôte

Country Status (5)

Country Link
US (1) US8486408B2 (fr)
EP (1) EP2349291B1 (fr)
AU (1) AU2009298122B2 (fr)
CA (1) CA2739454C (fr)
WO (1) WO2010040096A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
CA2794483C (fr) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista, une proteine mediatrice regulatrice des lymphocytes t, agents de liaison a vista et utilisation associee
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
TWI677507B (zh) 2012-06-22 2019-11-21 達特茅斯學院基金會 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
EP2892558B1 (fr) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Modulateurs vista de diagnostic et de traitement de cancer
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN119775416A (zh) 2013-12-24 2025-04-08 杨森制药公司 抗vista抗体及片段
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
ES2816630T3 (es) * 2014-07-30 2021-04-05 Genome Prot Inc Composiciones de flagelina y usos
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
EP3722314A1 (fr) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anticorps anti-vista et fragments
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
EP3448412A4 (fr) 2016-04-15 2020-03-25 Immunext Inc. Anticorps anti-vista humain et leur utilisation
US12440536B2 (en) 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
KR102169663B1 (ko) * 2019-03-28 2020-10-26 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085933A1 (fr) * 2001-04-20 2002-10-31 The Institute For Systems Biology Ligands de recepteur de type 5 et procedes d'utilisation
WO2005030133A2 (fr) * 2003-09-22 2005-04-07 Yale University Traitement utilisant des agonistes des recepteurs toll
WO2007103048A2 (fr) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Conjugués de protéine agoniste de tlr (flagelline)/agoniste de cd40/ antigène et d'adn et leur utilisation pour induire un renforcement synergique de l'immunité

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886748A (en) * 1986-03-11 1989-12-12 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5888810A (en) * 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US6211159B1 (en) * 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085933A1 (fr) * 2001-04-20 2002-10-31 The Institute For Systems Biology Ligands de recepteur de type 5 et procedes d'utilisation
WO2005030133A2 (fr) * 2003-09-22 2005-04-07 Yale University Traitement utilisant des agonistes des recepteurs toll
WO2007103048A2 (fr) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Conjugués de protéine agoniste de tlr (flagelline)/agoniste de cd40/ antigène et d'adn et leur utilisation pour induire un renforcement synergique de l'immunité

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEGRE M-L ET AL: "The multiple facets of toll-like receptors in transplantation biology", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 86, no. 1, 15 July 2008 (2008-07-15), pages 1 - 9, XP009131164, ISSN: 0041-1337 *
LOMBARDO E: "Toll-like receptor signaling: Involvement in graft transplantation", IMMUNOLOGIA, EDICIONES DOYMA, BARCELONA, ES, vol. 27, no. 2, 1 April 2008 (2008-04-01), pages 69 - 77, XP009131165, ISSN: 0213-9626 *

Also Published As

Publication number Publication date
EP2349291A2 (fr) 2011-08-03
US8486408B2 (en) 2013-07-16
EP2349291B1 (fr) 2012-12-05
AU2009298122B2 (en) 2015-01-15
US20110206699A1 (en) 2011-08-25
CA2739454C (fr) 2018-05-01
AU2009298122A1 (en) 2010-04-08
CA2739454A1 (fr) 2010-04-08
WO2010040096A2 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2010040096A3 (fr) Procédés pour le traitement d’une réaction de greffe contre hôte
PH12013500826A1 (en) Means and methods for treating dlbcl
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MY152149A (en) Prevention and treatment of sub-clinical pcvd
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
MY160041A (en) Compositions and methods for treating parasitic infections
EP2603227A4 (fr) Traitement amélioré utilisant des cellules hématopoïétiques souches et progénitrices
EP4406557A3 (fr) Matériaux et procédés pour améliorer la fonction gastro-intestinale
MX2009005466A (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
MX368173B (es) Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
EP3064220A3 (fr) Compositions et procédés pour le traitement d'infections et de tumeurs
IN2012DN02645A (fr)
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
IN2013MN00601A (fr)
NZ599875A (en) Human il-23 antigen binding proteins
IL194214A0 (en) Gpr119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
MX337041B (es) Cepas y metodos para mejorar la salud y/o desempeño de los rumiantes.
TW200714289A (en) Treatment of bone disorders
MX2009005460A (es) (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
GEP201706605B (en) Antibodies for epidermal growth factor receptor 3 (her3)
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
MX2012006406A (es) Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
MX2010008874A (es) Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793293

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009793293

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2739454

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13121016

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2009298122

Country of ref document: AU

Date of ref document: 20091002

Kind code of ref document: A